What's the cheapest weight loss medication in 2026?

I looked at the pricing for all 7 FDA-approved weight loss drugs available in 2026. The spread is staggering — the cheapest option costs about the same as a streaming subscription, while the most expensive runs more than many people's car payment.

Two years ago, the conversation about weight loss medication cost was simple and depressing: effective treatment meant GLP-1 injections, and GLP-1 injections meant $1,000 or more per month. If you didn't have insurance that covered it, you were essentially priced out of the most effective drugs on the market.

That changed dramatically in late 2025 and early 2026. The arrival of GLP-1 pills — oral semaglutide (the Wegovy pill) and orforglipron (Foundayo) — brought the cost of modern weight loss treatment down by roughly 90%. And the older drugs that were always affordable got even cheaper as generics expanded. The result is a landscape where most people can find something effective at a price they can actually sustain.

Here's every option, organised from cheapest to most expensive, with the clinical trial data behind each one so you can weigh cost against effectiveness.

The budget tier: under $100 a month

If cost is the primary constraint, there are two FDA-approved options that have been around for over a decade and are now available as generics or over the counter. Neither is as powerful as the newer GLP-1 drugs, but both have solid clinical evidence behind them — and they cost a fraction of the price.

Generic phentermine/topiramate (Qsymia) runs $30–$80 per month depending on the pharmacy. It's a combination of a stimulant appetite suppressant and an anti-seizure drug that also reduces appetite. In the CONQUER trial, participants on the full dose lost an average of 9.8% of their body weight over 56 weeks — that's roughly 22 lbs for someone starting at 220 lbs. The main side effects are tingling in the hands and feet (20% of participants), dry mouth (21%), and some people report a kind of mental fog from the topiramate component. It's a controlled substance, so you'll need a prescription and regular follow-ups.

Alli (orlistat 60mg) is $40–$60 per month and available over the counter without a prescription. It works completely differently from every other drug on this list — instead of suppressing appetite in the brain, it blocks about 30% of the fat you eat from being absorbed in the gut. The weight loss is more modest (around 5–6% of body weight in trials), and the GI side effects are well-known — oily stools, urgency, and occasional accidents, especially if you eat high-fat meals. Many people find the side effects actually help them stick to a lower-fat diet. The 4-year XENDOS trial showed it reduced progression to type 2 diabetes by 37%, which is a meaningful health benefit beyond weight loss alone.

The GLP-1 pill revolution: around $149 a month

This is where the landscape shifted. Until late 2025, GLP-1 drugs — the class that includes Ozempic, Wegovy, and Zepbound — were only available as injections costing $1,000 or more per month. Now there are two pill versions that deliver similar results at about a tenth of the price.

Oral Wegovy (semaglutide 25mg pill), approved in December 2025, produced 13.6% average weight loss in the OASIS 4 trial over 64 weeks. Among people who took it consistently, that figure climbed to 16.6%. It costs about $149 per month self-pay through Novo Nordisk's patient programme, and as little as $25 per month with commercial insurance. The catch is the dosing ritual: you take it first thing in the morning on an empty stomach with no more than 4 ounces of water, then wait at least 30 minutes before eating or drinking anything else. For some people that's no big deal. For others, especially those with unpredictable morning routines, it's a genuine hassle.

Foundayo (orforglipron), approved in April 2026 by Eli Lilly, is the first GLP-1 pill with no food or water restrictions at all. Take it whenever you want, with or without food. In the ATTAIN-1 trial, it produced 12.4% average weight loss at the highest dose over 72 weeks. Pricing starts at $149 per month for the lowest dose and goes up to $349 per month for the highest dose through LillyDirect. With commercial insurance savings cards, it can drop to about $25 per month. Medicare Part D coverage is expected from July 2026 at around $50 per month.

The difference between these two pills is mostly about convenience. Oral Wegovy edges out Foundayo slightly on weight loss (13.6% vs 12.4%), but Foundayo has no food timing restrictions. Same price tier, same drug class, slightly different trade-offs. For most people, the one their insurance covers better will be the deciding factor.

The middle ground: $100–$400 a month

Contrave (naltrexone/bupropion) sits in this range at $100–$400 per month depending on whether you get brand or generic. It's a twice-daily pill that combines an opioid blocker with an antidepressant. The weight loss is more modest — 6.1% in the COR-I trial — but it works on a completely different pathway than GLP-1 drugs. It targets the brain's reward and craving circuits, which makes it potentially more useful for people whose weight is driven by emotional eating or food cravings rather than pure appetite. The bupropion component also functions as an antidepressant, which can be a benefit or a complication depending on your situation. It's important to know that Contrave cannot be combined with opioid medications — the naltrexone will block them.

The injection tier: $650 and up

The injectable GLP-1 drugs remain the most effective options by the numbers, but they're also the most expensive. Whether the extra weight loss justifies the extra cost depends entirely on your financial situation and insurance coverage.

Zepbound (tirzepatide) produced the highest weight loss of any approved drug — up to 20.9% in the SURMOUNT-1 trial. It's a once-weekly injection that activates two appetite-regulating pathways (GIP and GLP-1) instead of just one. List price is about $1,086 per month, but Eli Lilly's LillyDirect programme brings it down to roughly $650 per month for self-pay patients. For a 220 lb person, 20.9% weight loss translates to about 46 lbs — roughly 16 lbs more than the best pill option would produce.

Wegovy injection (semaglutide 2.4mg) is about $1,350 per month at list price, making it the most expensive option. It produced 14.9% average weight loss in the STEP 1 trial and is the only weight loss drug proven to reduce heart attacks and strokes (the SELECT trial showed a 20% reduction in major cardiovascular events). If you have cardiovascular disease and obesity, this is the one with the strongest evidence for heart protection — but the same drug is available as a $149 pill if cost outweighs the slight difference in weight loss.

Saxenda (liraglutide) is an older daily injection at $800–$1,150 per month for the brand version, with generics starting to appear at a discount. It's less effective than the newer GLP-1 drugs (6–8% weight loss) and is now primarily used as a stepping stone — some insurers require you to try liraglutide before approving the more expensive options.

Insurance changes everything — but it's complicated

The self-pay prices above tell one story. Insurance tells a very different one. With the right coverage, a $1,350/month Wegovy injection can drop to $25/month, while a $30/month generic might stay about the same. The problem is that coverage varies enormously — by insurer, by plan, by state, and by which drug you're asking about.

Most commercial insurance plans now cover at least one GLP-1 drug for weight loss, but almost all require prior authorisation — your doctor has to submit paperwork proving you meet certain criteria (typically a BMI of 30 or above, or 27 with a weight-related health condition). Many also have step therapy requirements, meaning you have to try a cheaper drug first and show it didn't work before they'll approve the more expensive one.

Medicare Part D has been a major gap — it historically didn't cover anti-obesity medications at all. That's changing in 2026, with coverage for Foundayo (orforglipron) expected from July 2026 at approximately $50 per month. This is a significant shift for the millions of Medicare beneficiaries with obesity.

Both major GLP-1 manufacturers run savings programmes. Novo Nordisk's NovoCare savings card can bring Wegovy (injection or pill) down to about $25/month for commercially insured patients. Eli Lilly's LillyDirect programme offers Zepbound and Foundayo at reduced self-pay prices shipped direct to your door. These programmes are not available for Medicare, Medicaid, or other government-funded insurance.

Cost vs effectiveness: what the trade-off actually looks like

The most expensive drug (Wegovy injection at $1,350/month) produces about 14.9% weight loss. The cheapest GLP-1 pill (oral Wegovy at $149/month) produces about 13.6%. That's a 1.3 percentage point difference for roughly 10x the cost. For a 220 lb person, we're talking about a difference of approximately 3 lbs over the course of a year-long treatment.

On the other hand, the cheapest drug overall — generic Qsymia at $30/month — produces 9.8% weight loss, which is still clinically significant. It's about two-thirds the effectiveness of the best GLP-1 pill at one-fifth the price. The trade-off is different side effects (tingling, dry mouth, possible brain fog vs the GI effects of GLP-1 drugs) and a different mechanism that doesn't come with the cardiovascular benefits seen in the GLP-1 trials.

The most effective drug by raw numbers — Zepbound (tirzepatide) at up to 20.9% weight loss — costs $650/month through LillyDirect. That's about 7 percentage points more weight loss than the GLP-1 pills, which translates to roughly 15 additional pounds for someone starting at 220 lbs. Whether that extra weight loss is worth $500+ more per month is a personal financial question, not a medical one.